Raymond James & Associates Iovance Biotherapeutics, Inc. Transaction History

Raymond James & Associates

$161 Billion
Q3 2024

A detailed history of Raymond James & Associates transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, Raymond James & Associates holds 52,456 shares of IOVA stock, worth $636,815. This represents 0.0% of its overall portfolio holdings.

Number of Shares

52,456

Previous 59,919 12.46%

Holding current value

$636,815

Previous $480,000 2.5%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 18, 2024	SELL	$7.28 - $11.9 $54,330 - $88,809	-7,463 Reduced 12.46%	52,456 $492,000
Q2 2024 Jul 19, 2024	SELL	$7.78 - $14.19 $57,346 - $104,594	-7,371 Reduced 10.95%	59,919 $480,000
Q1 2024 Apr 22, 2024	BUY	$7.59 - $17.47 $382,384 - $880,138	50,380 Added 297.93%	67,290 $997,000
Q4 2023 Jan 16, 2024	BUY	$3.3 - $8.89 $12,764 - $34,386	3,868 Added 29.66%	16,910 $137,000
Q3 2023 Oct 24, 2023	BUY	$4.44 - $8.79 $555 - $1,098	125 Added 0.97%	13,042 $59,000
Q2 2023 Jul 25, 2023	BUY	$5.36 - $9.06 $14,472 - $24,462	2,700 Added 26.43%	12,917 $90,000
Q1 2023 Apr 14, 2023	BUY	$5.53 - $8.22 $56,500 - $83,983	10,217 New	10,217 $62,000
Q3 2022 Oct 25, 2022	BUY	$9.53 - $13.11 $476 - $655	50 Added 0.25%	19,863 $190,000
Q2 2022 Aug 12, 2022	BUY	$6.38 - $18.33 $28,244 - $81,146	4,427 Added 28.77%	19,813 $219,000
Q1 2022 May 11, 2022	BUY	$12.38 - $19.1 $66,233 - $102,185	5,350 Added 53.31%	15,386 $256,000
Q4 2021 Feb 08, 2022	BUY	$16.55 - $27.63 $29,740 - $49,651	1,797 Added 21.81%	10,036 $192,000
Q3 2021 Nov 02, 2021	SELL	$20.35 - $26.63 $177,574 - $232,373	-8,726 Reduced 51.44%	8,239 $203,000
Q2 2021 Aug 11, 2021	SELL	$16.33 - $33.07 $40,498 - $82,013	-2,480 Reduced 12.75%	16,965 $441,000
Q1 2021 May 14, 2021	SELL	$28.67 - $52.59 $53,125 - $97,449	-1,853 Reduced 8.7%	19,445 $616,000
Q4 2020 Feb 12, 2021	SELL	$28.04 - $50.26 $733,274 - $1.31 Million	-26,151 Reduced 55.11%	21,298 $988,000
Q3 2020 Nov 04, 2020	BUY	$27.75 - $36.3 $180,957 - $236,712	6,521 Added 15.93%	47,449 $1.56 Million
Q2 2020 Jul 28, 2020	BUY	$27.21 - $41.0 $1,360 - $2,050	50 Added 0.12%	40,928 $1.12 Million
Q1 2020 Apr 21, 2020	BUY	$19.54 - $38.85 $534,497 - $1.06 Million	27,354 Added 202.26%	40,878 $1.22 Million
Q4 2019 Feb 12, 2020	SELL	$17.95 - $29.41 $17,734 - $29,057	-988 Reduced 6.81%	13,524 $374,000
Q3 2019 Nov 07, 2019	SELL	$17.99 - $26.0 $77,015 - $111,306	-4,281 Reduced 22.78%	14,512 $264,000
Q2 2019 Aug 06, 2019	BUY	$9.78 - $24.52 $183,795 - $460,804	18,793 New	18,793 $461,000
Q3 2018 Nov 14, 2018	SELL	$11.25 - $17.7 $594,630 - $935,551	-52,856 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$12.45 - $16.95 $10,993 - $14,966	883 Added 1.7%	52,856 $677,000
Q1 2018 May 14, 2018	BUY	$8.1 - $19.5 $420,981 - $1.01 Million	51,973 New	51,973 $878,000

Others Institutions Holding IOVA

# of Institutions

317

Shares Held

240M

Call Options Held

1.27M

Put Options Held

1.68M

View Full List

About IOVANCE BIOTHERAPEUTICS, INC.

Ticker IOVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 157,800,992
Market Cap $1.92B
Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...

More about IOVA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Account

Raymond James & Associates Iovance Biotherapeutics, Inc. Transaction History